Repatha Shortage Update: What Patients Need to Know in 2026

Repatha Availability in 2026: What You Need to Know

If you take Repatha (evolocumab) to manage your cholesterol or reduce your cardiovascular risk, here's what you need to know about availability in 2026. While Repatha isn't facing a traditional drug shortage, the practical challenges of accessing this specialty biologic medication remain real for many patients.

Is Repatha Still in Shortage in 2026?

Repatha is not currently on the FDA drug shortage list. Amgen's manufacturing supply has been stable, and the medication itself is being produced in adequate quantities. However, "not in shortage" and "easy to get" are two very different things when it comes to specialty medications.

The real access barriers for Repatha in 2026 continue to be:

• Insurance prior authorization requirements that delay or deny coverage
• Specialty pharmacy distribution that limits where you can fill prescriptions
• High out-of-pocket costs for patients without adequate coverage or copay assistance

If you're struggling to get Repatha, the issue is almost certainly one of these factors — not a supply problem.

Why Is Repatha Still Hard to Find at Some Pharmacies?

Specialty Pharmacy Model

Repatha continues to be distributed primarily through specialty pharmacies. Most retail pharmacies (CVS, Walgreens, Walmart) don't stock it on their shelves because it requires refrigeration, has low prescription volume at individual locations, and costs $500–$700 per unit. This means you can't just walk in with a prescription and walk out with your medication the way you would with a statin or blood pressure pill.

Insurance Coverage Complexity

Prior authorization requirements for PCSK9 inhibitors have improved since the early days of Repatha's launch, but they remain a significant hurdle in 2026. Most insurers still require:

• Documentation of maximally tolerated statin therapy
• A completed trial of ezetimibe (step therapy)
• LDL-C above a specific threshold (varies by plan and indication)
• Diagnosis of familial hypercholesterolemia or established ASCVD

Some plans have streamlined their criteria, particularly for patients with documented cardiovascular disease, but others continue to impose restrictive requirements.

Formulary Preferences

Some insurance formularies prefer Praluent (alirocumab) over Repatha, or vice versa. If your plan covers the competing PCSK9 inhibitor preferentially, getting Repatha specifically may require an additional exception request.

How Much Does Repatha Cost in 2026?

Without Insurance

• Cash price: $500–$700 per month for the 140 mg prefilled syringe or autoinjector
• Annual list price: Approximately $5,850 per year (Amgen's net price after their 2018 reduction)
• 420 mg monthly dose (3 syringes or Pushtronex): Proportionally higher if not using copay assistance

With Insurance

• With Amgen copay card (commercial insurance): As low as $5 per month
• Without copay card: Specialty tier copays typically range $50–$200+ per month depending on plan
• Medicare Part D: Copay card not available; costs depend on your plan's coverage phase. May qualify for Extra Help or manufacturer patient assistance

Savings Programs

• Amgen Repatha Copay Card: Reduces cost to as low as $5/month for commercially insured patients. Enroll at repatha.com or call 1-844-REPATHA
• Amgen Safety Net Foundation: Free medication for uninsured/underinsured patients with household income at or below 400% of federal poverty level
• Amgen FIRST STEP: Helps patients experiencing access delays by providing temporary free medication while insurance issues are resolved

For a complete breakdown of savings options, see our guide to saving money on Repatha in 2026.

New Options in 2026

The cholesterol-lowering landscape continues to evolve:

• Leqvio (inclisiran) has gained broader insurance coverage since its launch, offering twice-yearly in-office injections as an alternative to monthly home injections
• Expanded PCSK9 inhibitor coverage: More insurers have simplified prior authorization criteria for patients with established ASCVD, making approval faster
• Biosimilar development: While no Repatha biosimilar is currently available in the US, several are in development, which could increase competition and lower costs in the coming years

How to Find Repatha in Stock Near You in 2026

1. Use Medfinder — search for pharmacies with Repatha available, including specialty pharmacies, without calling around yourself
2. Contact your insurance plan's preferred specialty pharmacy — this is usually the most reliable source and ensures insurance coverage
3. Plan ahead — contact your specialty pharmacy at least 1 week before your next injection is due to ensure timely delivery
4. Ask about home delivery — most specialty pharmacies offer cold-chain home delivery, which can be more convenient than pickup

Final Thoughts

Here's what to remember about Repatha access in 2026:

1. No manufacturing shortage — supply is stable, but access barriers persist
2. Prior authorization remains the biggest hurdle — work with your doctor to submit complete documentation upfront
3. Financial assistance is available — the Amgen copay card can reduce your cost to $5/month with commercial insurance
4. Specialty pharmacies are your primary source — don't waste time at retail pharmacies
5. Medfinder can help — let someone else navigate the pharmacy maze for you

For more information, read our guides on why Repatha is hard to find, how to find Repatha in stock, and alternatives to Repatha.